文献速递浆细胞疾病

来那度胺联合地塞米松治疗POEMS综合征患者:一项前瞻性、开放标签试验的结果

Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial.
PubMed 文献 · Br J Haematol · 2017-10-19

这项前瞻性、开放标签、先导研究评估来那度胺联合地塞米松(RD)方案治疗18例POEMS综合征患者(13例经治,5例新诊断但不适合大剂量治疗),主要终点为神经或临床改善比例,前15例中10例有效达到主要终点,18例中13例(72%)有效,3年无进展生存率59%。

要点

  • 18例POEMS综合征患者接受RD方案,前15例中10例有效达到主要终点。
  • 18例中13例(72%)有效,9例同时获得临床和神经改善。
  • 随访39个月时全部患者存活,3年无进展生存率59%,无患者因毒性停药。

核心结论

  • RD方案在多数POEMS综合征患者中显示出高比例的持久症状改善且耐受性良好。

研究设计与样本

  • 前瞻性、开放标签、先导研究,纳入18例POEMS综合征患者(13例经治,5例新诊断但不适合大剂量治疗)。
  • 治疗为6个周期来那度胺(25 mg/天,用21天休7天)联合地塞米松(40 mg/周一次),6周期后有效者继续治疗至进展或不可耐受毒性。
  • 主要终点为神经或临床改善的患者比例,若前15例中9例有效则认为RD方案值得进一步评估。

主要发现

  • 前15例入组患者中观察到10例有效,达到主要终点。
  • 18例中15例(83%)完成6个RD周期,其中13例(72%)有效,9例同时有临床和神经改善。
  • 完成6周期的15例中,4例在25个月随访时仍在治疗。
  • 随访39个月时全部患者存活,3年无进展生存率为59%。
  • 无患者因毒性停用RD。

关键数值与推荐

  • 若前15例中9例有效则认为RD方案值得进一步评估,实际观察到10例有效。
  • 18例中13例(72%)有效,9例同时有临床和神经改善。
  • 3年无进展生存率为59%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Given its anti-angiogenic activity, lenalidomide may have a role in the treatment of POEMS (Peripheral neuropathy, Organomegaly, Endocrinopathy, Monoclonal plasma cell disorder and Skin changes) syndrome. This prospective, open-label, pilot study evaluated the combination of lenalidomide + dexamethasone (RD) in 18 POEMS syndrome patients (13 pre-treated, 5 newly-diagnosed but ineligible for high-dose therapy). Treatment consisted of six cycles of lenalidomide (25 mg/day for 21 days followed by 7 days rest) plus dexamethasone (40 mg/once a week). Patients responding after six cycles continued treatment until progression or unbearable toxicity. The primary endpoint was the proportion of patients with either neurological or clinical improvement. The RD combination was considered as deserving further evaluation if 9 of the first 15 patients responded. Ten responses were observed among the first 15 enrolled patients, meeting the primary endpoint. Fifteen of 18 patients (83%) completed six RD cycles: 13 (72%) patients responded and nine had both clinical and neurological improvement. Among the 15 patients who completed the six RD cycles, four were still on treatment after a 25-month follow-up. At 39 months of follow-up, all patients were alive with a 3-year progression-free survival of 59%. No patient discontinued RD for toxicity. Overall, the RD regimen showed a high incidence of prolonged symptoms improvement and was well tolerated in most POEMS patients.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Nozza A, Terenghi F, Gallia F, et al. Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial. Br J Haematol. 2017. PMID: 29048107. doi:10.1111/bjh.14966

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。